Project Grant R01HL181965
Award Date 7/1/26
Completion Date 3/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Norfolk, VA 23507, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Vermont & State Agricultural College a $713,511 Project Grant on August 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms by which mutations in the MYBPC3 gene lead to hypertrophic cardiomyopathy (HCM). The research examines how reduced levels of myosin-binding protein C (MyBP-C) disrupts myosin function and thick filament...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University $1.4 million under the Cardiovascular Diseases Research program (CFDA 93.837) on August 18, 2025, for research into the biological basis of cardiac thick filament regulation. The project, which extends through May 31, 2029, investigates the molecular mechanisms by which cardiac myosin and cardiac myosin-binding protein-C (cMyBP-C) regulate force generation in cardiac muscle. The...
- Federal Grant Award Summary Michigan Technological University received a $589,998 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2028. The award supports research investigating cardiac sensory and sympathetic nerve dysregulation in hypertrophic cardiomyopathy (HCM), a genetic heart disease affecting approximately 1 in 500 individuals and representing the...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $229,152 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 27, 2025, with completion targeted for March 31, 2028. The award funds research to visualize the structure and function of native cardiac sarcomere proteins in hypertrophic cardiomyopathy (HCM), the most common genetic cardiovascular disorder....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, San Diego a $1,507,470 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 1, 2025, through May 31, 2029, to investigate the gene regulatory mechanisms controlling cardiac myosin heavy chain (MYH) expression and isoform switching. The research will employ a multidisciplinary approach to examine cis-regulatory sequences and trans-acting factors that...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington $882,498 under CFDA 93.837 (Cardiovascular Diseases Research) on May 1, 2026, to develop computational and experimental models of myosin variants. The project, concluding February 28, 2030, delivers integrated tools and research outputs to elucidate how single amino acid variants affect myosin structure and function across multiple biological scales. The deliverables...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $776,791 Project Grant to The Washington University on June 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating how sequence changes in intrinsically disordered regions (IDRs) of cardiac troponin affect protein function and cardiac contraction regulation. The project, which extends through April 30, 2029, addresses a critical gap in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $553,217 to the University of Colorado-Denver on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Hat-Dependent Control of Cardiac Fibrosis," will extend through May 31, 2029, and focuses on understanding and developing targeted therapeutic interventions to prevent pathological fibrotic remodeling in the heart. The...
- Federal Project Grant Award Summary The University of Virginia received a $117,552 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective January 4, 2026, with completion targeted for June 30, 2027. The award funds basic research investigating the mechanistic role of lymphatic endothelial alpha globin (HBA) in cardiometabolic heart failure (CMHF), a condition affecting over three million Americans...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...